U.S. Launches Section 301 Investigation Into Germany's Drug Pricing Policy on Thursday

According to Jin10, the U.S. launched a Section 301 trade investigation into Germany's drug pricing policy on Thursday evening (June 19). The probe targets Germany's plan, announced in April, requiring pharmaceutical companies to increase drug discounts, potentially saving billions of dollars annually to address public healthcare system funding gaps. U.S. Trade Representative Grier stated that President Trump emphasized the global pharmaceutical R&D costs should not be borne disproportionately by American patients. The European Parliament's International Trade Committee chair criticized the move as sovereign interference.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments